Reports
Published: 2019-02-06 08:12:28
PERIOD (JANUARY–DECEMBER 2018) SIGNIFICANT EVENTS IN THE FOURTH QUARTER SIGNIFICANT EVENTS DURING THE PERIOD SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD Lars Hedbys, CEO Idogen AB Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com
FOURTH QUARTER (OCTOBER–DECEMBER 2018)
CONDENSED EARNINGS AND CASH FLOW
(Amounts in KSEK unless otherwise stated)
2018
2017
2018
2017
3 months
3 months
12 months
12 months
Oct-Dec
Oct-Dec
Jan-Dec
Jan-Dec
Other operating income
3,766
0
3,766
0
Operating expenses
-8,562
-7,289
-31,627
-21,299
Operating loss
-4,796
-7,289
-27,861
-21,299
Loss for the period after net financial items
-4,806
-7,315
-27,634
-21,322
Average number of shares
24,998,490
20,778,472
21,843,166
16,207,516
Average number of warrants
8,555,883
17,111,766
11,790,710
7,969,864
Loss per share before dilution (SEK)
-0.19
-0.35
-1.27
-1.32
Loss per share after dilution (SEK)
-0.19
-0.35
-1.27
-1.32
Cash flow from operating activities
-432
-8,250
-10,394
-19,906
KEY FIGURES
Working capital
42,306
33,894
42,306
33,894
Acid-test ratio (%)
305
895
305
895
Equity/assets ratio (%)
71
90
71
90
Loss per share before dilution
-0.19
-0.35
-1.27
-1.32
Average number of shares
24,998,490
20,778,472
21,843,166
16,207,516
For additional information, please contact:
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 6th of February 2019.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient"s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com